Clinical trial

A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients

NCT04237584

Drugs and interventions used in this trial

6 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Enzalutamide during Lead-in Period Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Lead-in Enzalutamide followed by Radium-223/Enzalutamide Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Lead-in Enzalutamide followed by Placebo/Enzalutamide Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Darolutamide during Lead-in Period Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Lead-in Darolutamide followed by Radium-223/Darolutamide Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Lead-in Darolutamide followed by Placebo/Darolutamide Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2020-06-30

PhasePHASE3

Conditions

Metastatic Castration-resistant Prostate Cancerunresolved

Interventions

Enzalutamide during Lead-in PeriodDRUG

Lead-in Enzalutamide followed by Radium-223/EnzalutamideDRUG

Lead-in Enzalutamide followed by Placebo/EnzalutamideDRUG

Darolutamide during Lead-in PeriodDRUG

Lead-in Darolutamide followed by Radium-223/DarolutamideDRUG

Lead-in Darolutamide followed by Placebo/DarolutamideDRUG

Sponsors & collaborators

MANA RBMlead sponsor

Bayercollaborator

Carolina Urologic Research Centercollaborator

Tulane Universitycollaborator

Barbara Ann Karmanos Cancer Institutecollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04237584 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.